NCT02165618

Brief Summary

Polypharmacy is a common problem in elderly, leading among others to increased adverse drug events. The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team using the RASP (Rationalisation of drugs on admission by an adjusted STOPP\*-list in older patients) list could reduce inappropriate prescribing for elderly admitted patients, admitted to non-geriatric departments. (\* = Screening Tool of Older Persons' potentially inappropriate Prescriptions)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2014

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2014

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 26, 2014

Completed
22 days until next milestone

First Posted

Study publicly available on registry

June 17, 2014

Completed
Last Updated

June 17, 2014

Status Verified

May 1, 2014

Enrollment Period

1 month

First QC Date

May 26, 2014

Last Update Submit

June 13, 2014

Conditions

Iatrogenic Disease

Keywords

frailtygeriatric, elderlypolypharmacy

Outcome Measures

Primary Outcomes (1)

  • Number of medication-related recommendations by the geriatric consultation team.

    The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

Secondary Outcomes (3)

  • Number of potentially inappropriate drugs at discharge, as identified by the RASP list.

    The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

  • Number of drugs at discharge, relative to the drugs on admission.

    The number was ascertained at time of discharge from the ward, taking into account an average hospital stay of 14 days.

  • Acceptance rate of the GCT interventions by the treating physician.

    Up to 72 hours after the GCT had given its recommendations.

Study Arms (2)

GCT

NO INTERVENTION

In a before phase, data on how the GCT operated (i.e. good clinical practice) was gathered.

GCT-RASP

ACTIVE COMPARATOR

Medication review, based on but not limited to the RASP list

Other: Medication review, based on but not limited to the RASP list

Interventions

Medication review, based on but not limited to the RASP listOTHER

Systematic approach: 1. Medication reconciliation 2. Applying the RASP list 3. Expert review (not based on the RASP list) 4. Multidisciplinary discussion

Also known as: RASP, RASP list, Systematic medication review
GCT-RASP

Eligibility Criteria

Age75 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Admitted to a non-geriatric ward
  • years or older
  • Dutch speaking
  • Consultation by the GCT

You may not qualify if:

  • End-of-life
  • No drugs on admission

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals Leuven

Leuven, Flemish Brabant, 3000, Belgium

Location

Related Publications (1)

  • Van der Linden L, Hias J, Dreessen L, Milisen K, Flamaing J, Spriet I, Tournoy J. Medication review versus usual care to improve drug therapies in older inpatients not admitted to geriatric wards: a quasi-experimental study (RASP-IGCT). BMC Geriatr. 2018 Jul 3;18(1):155. doi: 10.1186/s12877-018-0843-y.

    PMID: 29970005DERIVED

MeSH Terms

Conditions

Iatrogenic DiseaseFrailty

Interventions

Medication Review

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Medication SystemsOrganization and AdministrationHealth Services AdministrationPatient Care Management

Study Officials

  • Lorenz R Van der Linden, PharmD

    Universitaire Ziekenhuizen KU Leuven

    PRINCIPAL INVESTIGATOR

  • Johan Flamaing, MD, PhD

    Universitaire Ziekenhuizen KU Leuven

    PRINCIPAL INVESTIGATOR

  • Jos Tournoy, MD, PhD

    Universitaire Ziekenhuizen KU Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2014

First Posted

June 17, 2014

Study Start

January 1, 2014

Primary Completion

February 1, 2014

Study Completion

February 1, 2014

Last Updated

June 17, 2014

Record last verified: 2014-05

Locations

BE(1)